Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKLR | P30613 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25233970 | 1.00 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL25275480 | 0.90 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6 | |
| SCHEMBL25234017 | 0.89 | CHRM5 (0.80) | CHRM5CYP3A4CYP2D6PKMNPC1 | |
| SCHEMBL25231579 | 0.88 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL30456359 | 0.86 | CHRM5 (0.75) | CHRM5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL25281579 | 0.86 | CHRM5 (0.75) | CHRM5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL25227463 | 0.84 | CHRM5 (0.90) | CHRM5CYP3A4CYP2D6 | |
| SCHEMBL30456555 | 0.84 | CHRM5 (0.78) | CHRM5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL25279556 | 0.84 | CHRM5 (0.73) | CHRM5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL25279427 | 0.83 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | CHRM5 1/4885CYP3A4 520/4885CYP2D6 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.